Pyxis Oncology
PYXS
73 hedge funds and large institutions have $59.7M invested in Pyxis Oncology in 2025 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 31 reducing their positions, and 15 closing their positions.
98% more capital invested
Capital invested by funds: $30.2M → $59.7M (+$29.5M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 15
1.06% less ownership
Funds ownership: 44.32% → 43.26% (-1.1%)
1% less funds holding
Funds holding: 74 → 73 (-1)
65% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$1.7M |
| 2 |
SC
Stempoint Capital
New York
|
+$993K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$855K |
| 4 |
LP
Longaeva Partners
Chicago,
Illinois
|
+$725K |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$603K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.92M |
| 2 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$1M |
| 3 |
BlackRock
New York
|
-$350K |
| 4 |
P8IP
Pier 88 Investment Partners
San Francisco,
California
|
-$310K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$163K |
PYXS Hedge Fund Activity: Q3 2025 in Review
73 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q3 2025, worth a combined $59.7M — up 98% from $30.2M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of PYXS and 14 opened new positions — a net loss of 1 holder — while 31 trimmed existing stakes and 11 added.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $1.7M. The largest seller was Millennium Management, cutting an estimated $3.92M.
- 73 institutional investors held Pyxis Oncology (PYXS) as of Q3 2025, down from 74 in Q2 2025.
- Funds reported $59.7M of Pyxis Oncology stock for Q3 2025, up 98% quarter-over-quarter.
- 14 funds opened new Pyxis Oncology positions in Q3 2025 and 15 closed out, a net change of -1 holder.
- The largest Pyxis Oncology buyer in Q3 2025 was Perceptive Advisors, an estimated $1.7M added.
- The largest Pyxis Oncology seller in Q3 2025 was Millennium Management, an estimated $3.92M sold.
Based on aggregated 13F filings for Q3 2025.